HENGRUI PHARMA - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

or completeness of this announcement, and expressly expressly disclaims any liability arising out of or in reliance upon the whole or any part of the contents of this announcement. assumes no responsibility for any losses caused by such content.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Jiangsu Hengrui Pharmaceutical Co., Ltd.

(a joint stock limited company incorporated in the People's Republic of China) (Stock code: 1276)

Overseas regulatory announcement

This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

In accordance with the relevant laws and regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceutical Co., Ltd. (the "Company")

The Shanghai Stock Exchange website (www.sse.com.cn) published the following announcement. They are listed below for reference only.

By order of the board of directors Jiangsu Hengrui Pharmaceutical Co., Ltd. Chairman

Mr. Sun Piaoyang

Shanghai, China March 25, 2026

As at the date of this announcement, members of the Board of Directors include (i) Executive Directors Mr. Sun Piaoyang, Mr. Dai Hongbin, and Mr. Feng Jinu; Mr. Zhang Lianshan, Mr. Jiang Ningjun and Mr. Sun Jieping; (ii) Ms. Guo Congzhao, a non-executive director; and (iii)

Independent non-executive directors are Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Zhou Ji'en.

Securities code: 600276 Securities abbreviation: Hengrui Medicine Announcement number: Lin 2026-050

Jiangsu Hengrui Pharmaceutical Co., Ltd.

About the joint-stock company Shanghai Ruihongdi Pharmaceutical Co., Ltd.

Announcement of Capital Increase and Related Transactions

The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records or misleading statements.

or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its content.

Important content reminder:

 Name of investment target

Shanghai Ruihongdi Pharmaceutical Co., Ltd. (hereinafter referred to as "Ruihongdi" or "subject company")

 Investment amount

Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as "Hengrui Pharmaceutical" or the "Company") is a joint-stock company

The current shareholders of Shanghai Ruihongdi Pharmaceutical Co., Ltd. plan to increase their capital in RMB in the same proportion through monetary investment.

750 million yuan, of which Hengrui Pharmaceutical increased its capital by RMB 285 million and Jiangsu Hengrui Pharmaceutical Group Co., Ltd.

(hereinafter referred to as "Hengrui Group") increased its capital by RMB 210 million, and Shanghai Shengdi Biopharmaceutical Private Equity Investment

Capital Fund Partnership (Limited Partnership) (hereinafter referred to as "Shengdi Fund") increased its capital by RMB 142.5 million.

Shenzhen Yingtai Asset Management Co., Ltd. (hereinafter referred to as "Yingtai Asset Management") increased its capital by RMB 11,250

Ten thousand yuan.

 This transaction constitutes a related transaction

 This transaction does not constitute a major asset restructuring

 Transactions conducted with the same related person in the past 12 months and the same transactions conducted with different related persons

The cumulative number and amount of transactions related to the transaction category

In addition to the daily related transactions disclosed by the company in its regular reports or interim reports, as of the date of this announcement,

The company has not had any transactions with the same related person or transactions with different related persons in the past 12 months.

Related transactions under the same transaction category.

 Approval and other related procedures that need to be performed before the transaction is implemented

This transaction has been reviewed by a special meeting of the company’s independent directors and the 24th meeting of the ninth board of directors.

If approved, it does not need to be submitted to the company's shareholders' meeting for review, and does not need to be approved by relevant departments.

1. Overview of related-party external investment

(1) Basic overview of foreign investment

1. Overview of this transaction

In order to promote the business development of Shanghai Ruihongdi Pharmaceutical Co., Ltd., the current shareholders of Ruihongdi plan to invest in it in currency

Capital increase in the same proportion. According to the "Asset Appraisal Report" issued by Zhongfa International Asset Appraisal Co., Ltd. (China

(Public Appraisal Report [2026] No. 16), as of December 31, 2025, the base date of assessment, all shareholders of Ruihongdi

The book value of the department’s equity is -66.2652 million yuan, the appraised value is 1.0877179 million yuan, and the appraised value has increased

1,153.9831 million yuan, with a value-added rate of 1,741.46%.

All parties agree that in this capital increase, the capital increase parties will increase capital to the target company by a total of RMB 750 million.

The target company's new registered capital increased by RMB 98.6842 million, making the target company's registered capital increase from RMB

RMB 131,578,900 increased to RMB 230,263,200. Among them, Hengrui Medicine increased its investment with its own funds.

RMB 285 million, and the target company’s new registered capital was RMB 37.5 million; Hengrui Group increased its registered capital by RMB 37.5 million;

capital of RMB 210 million, and the subscribed target company’s new registered capital was RMB 27.6316 million; Shengdi

The fund increased its capital by RMB 142.5 million, and the target company's new registered capital was RMB 18.75 million;

Yingtai Asset Management increased its capital by RMB 112.5 million, subscribing to the target company’s new registered capital of RMB

14.8026 million yuan.

After the capital increase is completed, the shareholding proportions of the company, Hengrui Group, Shengdi Fund and Yingtai Asset Management

Still 38%, 28%, 19%, 15%.

2. Transaction elements of this transaction

□Newly established company √Increase capital in existing companies (√Same proportion □Not the same proportion) --Type of company before capital increase: □ Wholly owned subsidiary □ Holding subsidiary investment type √Company with shareholding □Company without shareholding □Invest in new projects □Others:______

Investment target name Shanghai Ruihongdi Pharmaceutical Co., Ltd.

√ Determined, specific amount (10,000 yuan): 28,500_ Investment amount  Not yet determined √Cash

√ Own funds □Raise funds □Bank loan Investment method □Others:_____ □Physical assets or intangible assets □Equity □Others:______

Is it cross-border □Yes √No

(2) Review status of the board of directors

This transaction has been reviewed and approved by the company’s special meeting of independent directors and the 24th meeting of the ninth board of directors.

However, it does not need to be submitted to the company's shareholders' meeting for review, and does not need to be approved by relevant departments.

(3) This transaction constitutes a related transaction, but does not constitute a

Major asset reorganization stipulated in the Law. (4) As of this related transaction, the company’s listed companies and the same related person or parties in the past 12 months have

Related party transactions related to the same transaction category between different related parties have not reached the listed company’s latest

The absolute value of the audited net assets is 5%.

2. Basic information on the shareholders (including related persons) of the capital increase target

(1) Basic information on related parties

1. Jiangsu Hengrui Pharmaceutical Group Co., Ltd. (related party)

(1) Basic company information Full name of legal person/organization Jiangsu Hengrui Pharmaceutical Group Co., Ltd.

√ 913207001389765678_ Unified social credit code □ Not applicable

Legal representative Sun Piaoyang Date of establishment 1996/12/6

Registered capital 50 million yuan

Paid-in capital 50 million yuan Registered address: Community 07-12, Lianyungang Economic and Technological Development Zone

Main office address: Community 07-12, Lianyungang Economic and Technological Development Zone Sun Piaoyang holds 89.22% of the shares, and Wuxi Hongda Investment Co., Ltd. Major shareholders 10.78% Relationship with the target company Current shareholders of the target company

Main business: industrial investment, investment management and consulting services. √Controlling shareholders, actual controllers and other companies they control

□Controlled by directors, supervisors, senior management and their close family members and the above-mentioned entities Association relationship type of enterprises □Others,_______ Whether it is a listed company this time Joint investment in capital increase √Yes □No Capital

(2) Financial data for the latest year and period

Unit: 10,000 yuan

Subject December 31, 2024 December 31, 2025

Total assets 1,476,301.33 1,458,764.77 Total liabilities 245,819.76 247,815.60

Total owners’ equity 1,230,481.57 1,210,949.17 Asset-liability ratio 16.65% 16.99%

Subjects 2024 2025

Operating income 0 0 Net profit 147,513.12 467.60

The financial data for 2024 have been audited, and the financial data for 2025 have not been audited. Hengrui Group exists in accordance with the law and operates normally, with good financial and credit status. Hengrui Group is a public company

The company is the controlling shareholder of the company. In addition to Mr. Sun Piaoyang, the executive director of Hengrui Group, who serves as the chairman of the company, the company and Hengrui Group have

Rui Group has no other relationships in terms of property rights, business, assets, creditor's rights, debts, personnel, etc.

2. Shanghai Shengdi Biopharmaceutical Private Equity Investment Fund Partnership (Limited Partnership) (Related Party)

(1) Basic company information Shanghai Shengdi Biopharmaceutical Private Equity Investment Fund Partnership (Limited Partnership) Full name of legal person/organization Guy) √ 91310000MABPNFMC45_ Unified social credit code □ Not applicable

Executive Partner Shanghai Shengdi Private Equity Fund Management Co., Ltd. Date of establishment 2022/6/8

Registered capital 2.06 billion yuan

Paid-in capital 618 million yuan Registered address: 3rd Floor, No. 665, Zhangjiang Road, China (Shanghai) Pilot Free Trade Zone

Main office address: No. 1288 Haike Road, Pudong New District, Shanghai Jiangsu Hengrui Pharmaceutical Co., Ltd. holds 48.54% of the share, Jiangsu Major shareholders Hengrui Pharmaceutical Group Co., Ltd. holds 48.54% share Relationship with the target company Current shareholders of the target company

Engage in equity investment, investment management, asset management, etc. with private equity funds Main business activities. □Controlling shareholders, actual controllers and other companies they control □Controlled by directors, supervisors, senior management and their close family members and the above-mentioned entities of enterprises Association relationship type √Others: The members of Shengdi Fund’s investment decision-making committee include company directors Mr. Zhang Lianshan, Executive Vice President and Mr. Liu Jianjun, Chief Financial Officer, Based on the principle of prudence, the company identified Shengdi Fund as a related party of the company. Whether it is a listed company this time Joint investment in capital increase √Yes □No Capital

(2) Financial data for the latest year and period

Unit: 10,000 yuan

Subject December 31, 2024 December 31, 2025

Total assets 61,201.77 61,648.48 Total liabilities 0 0

Total owners’ equity 61,201.77 61,648.48

Asset-liability ratio 0 0 Subjects 2024 2025

Operating income 0 0 Net profit -403.99 446.71

The financial data for 2024 have been audited, and the financial data for 2025 have not been audited.

Shengdi Fund exists in accordance with the law and is operating normally, with good financial and credit status. Shengdi Fund is a public

A partnership jointly established by the company and its subsidiaries Shanghai Shengdi Private Equity Management Co., Ltd. and Hengrui Group

industry, the company’s director and executive vice president Mr. Zhang Lianshan and financial director Mr. Liu Jianjun invested in Shengdi Fund

Member of the decision-making committee.

3. Shenzhen Yingtai Asset Management Co., Ltd. (related party)

(1) Basic company information

Full name of legal person/organization Shenzhen Yingtai Asset Management Co., Ltd.

√ 91440300335388561T _ Unified social credit code □ Not applicable Legal representative Cen Junda

Date of establishment 2015/5/8

Registered capital 10 million yuan Paid-in capital 10 million yuan

No. 1167 Yihai Avenue, Nanshan Street, Qianhai Shenzhen-Hong Kong Cooperation Zone, Shenzhen City Registered address W331, 3rd Floor, Maritime Center Port Building No. 1167 Yihai Avenue, Nanshan Street, Qianhai Shenzhen-Hong Kong Cooperation Zone, Shenzhen City Principal office address W331, 3rd Floor, Maritime Center Port Building Major shareholder Cen Junda holds 100% of the shares Relationship with the target company Current shareholders of the target company Trusted asset management (not allowed to engage in trust, financial asset management, insurance

insurance asset management, securities asset management and other businesses); investment consulting (to (excluding restricted items); equity investment; entrusted management of equity investment funds Main business Funds (not allowed to engage in securities investment activities; not raised in a public manner funds to carry out investment activities; shall not engage in public fund management industry services); entrusted investment management (excluding financial assets and other restricted items)

items); business information consulting, economic information consulting and other information consulting (excluding restricted projects); invest in setting up industries; provide investment consultation online Consulting services; marketing planning; domestic trade (excluding franchise, specialized

controlled, exclusive products). □Controlling shareholders, actual controllers and other companies they control □Controlled by directors, supervisors, senior management and their close family members and the above-mentioned entities Association relationship type of enterprises √Others: Enterprises controlled by natural persons associated with the company. Whether it is a listed company this time

Joint investment in capital increase √Yes □No Capital

(2) Financial data for the latest year and period

Unit: 10,000 yuan

Subject December 31, 2024 December 31, 2025 Total assets 58,853.03 58,954.21

Total liabilities 18,600.83 18,703.74 Total owners’ equity 40,252.20 40,250.47

Asset-liability ratio 31.61% 31.73%

Subjects 2024 2025 Operating income 0 0

Net profit -0.30 -1.73

The financial data for 2024 and 2025 are unaudited.

Yingtai Asset Management's financial and credit status have been good in the past three years. In addition to the actual control of Yingtai Asset Management Except for shareholders who directly or indirectly hold more than 5% of the company's shares, there are no other assets between them and the company.

rights, business, assets, credits and debts, personnel, etc.

3. Basic information on investment targets

(1) Overview of investment targets

Ruihongdi was established in August 2021. It is a company focusing on AAV gene therapy drugs and mRNA drugs.

and biotech companies developing cell therapy drugs. The R&D pipeline focuses on neurology, ophthalmology, oncology, blood vessels, Chronic wounds and other fields with great clinical demand and broad market development prospects.

(2) Specific information on investment targets

1. Basic information on the capital increase target

Investment type √Increase capital in existing company (√Same proportion □Not the same proportion) Type of target company (capital increase Joint stock company before) Full name of legal person/organization Shanghai Ruihongdi Pharmaceutical Co., Ltd.

√ 91310115MA7AP9AX34_ Unified social credit code □ Not applicable Legal representative Ning Wei

Date of establishment 2021/8/20

Registered capital 131,578,947 yuan

Paid-in capital 131,578,947 yuan

No. 13, No. 27, Xinjinqiao Road, China (Shanghai) Pilot Free Trade Zone Registered address Floor 2

Main office address: No. 399, Lianchuang Road, Pudong New District, Shanghai Actual controller Sun Piaoyang

Engaged in technology development, technical consulting, and technical services in the pharmaceutical field, Main business Technology transfer.

Industry C27 Pharmaceutical manufacturing industry

2. Financial data of the capital increase target in the latest year and period

Unit: 10,000 yuan December 31, 2024 December 31, 2025 subjects (Audited) (Unaudited) Total assets 24,668.12 24,979.77

Total liabilities 5,441.77 31,606.29 Total owners’ equity 19,226.35 -6,626.52

Asset-liability ratio 22.06% 126.53%

2024 2025 subjects (Audited) (Unaudited) Operating income 580.68 455.75 Net profit -14,660.10 -25,852.89

3. Equity structure before and after capital increase

Unit: 10,000 yuan

Before capital increase After capital increase Serial number Shareholder name Subscribed registered capital Subscribed registered capital Proportion Proportion Capital (10,000 yuan) Capital (10,000 yuan) 1 Hengrui Medicine 5,000.00 38% 8,750.00 38% 2 Hengrui Group 3,684.21 28% 6,447.37 28% 3 Shengdi Fund 2,500.00 19% 4,375.00 19%

4 Yingtai Asset Management 1,973.68 15% 3,453.95 15% Total 13,157.89 100% 23,026.32 100%

4. Evaluation and pricing of transaction targets

(1) Pricing situation and basis

1. Pricing method and results of this transaction

This valuation is conducted using the asset-based method. As of the valuation base date, December 31, 2025,

The book value of all Ruihongdi shareholders’ equity is -66.2652 million yuan, and the assessed value is 1.0877179 million yuan.

The estimated added value is 1,153.9831 million yuan, with a value-added rate of 1,741.46%.

All parties agree that the price of this capital increase will be determined based on the assessed value, and the capital increase price agreed upon through negotiation The registered capital is 7.60 yuan per yuan.

2. Specific evaluation and pricing of the underlying assets

Underlying asset name Shanghai Ruihongdi Pharmaceutical Co., Ltd.

□ Negotiate pricing √ Pricing based on assessment or valuation results Pricing method □Public listing method determined □Others: √Determined, specific amount (10,000 yuan): Hengrui Pharmaceutical invested RMB 28,500

The transaction price is RMB 10,000, and the target company’s new registered capital is RMB 37.5 million. □Not yet determined Assessment/valuation base date 2025/12/31

Adopt appraisal/valuation results √Asset-based method □Income method □Market method □Others, specifically: (single choice) Appraisal/valuation value: 108,771.79_ (10,000 yuan) Final assessment/valuation conclusion Appraisal/valuation appreciation rate: 1,741.46% Appraisal/valuation agency name Zhongfa International Asset Appraisal Co., Ltd.

The specific evaluation situation is as follows:

(1) Evaluation method According to the purpose of this evaluation, the evaluation object, and the type of value, combined with the data collection situation and the three evaluations

Regarding the applicable conditions of the basic method, the valuation method selected for this valuation is the asset-based method.

(2) Evaluation base date

December 31, 2025

(3) Evaluate assumptions

1. Basic assumptions:

① Open market assumption, that is, it is assumed that assets traded in the market or assets intended to be traded in the market, assets

Both parties to the property transaction have equal status, and both parties have the opportunity and time to obtain sufficient market information to facilitate

Make rational judgments about the functions, uses and transaction prices of assets;

②Transaction assumption, that is, it is assumed that all assets to be valued are already in the process of trading, and the appraiser will Assess trading conditions for assets and other simulated markets for valuation. Trading assumptions are one by which an asset valuation can be carried out

The most basic premise assumption;

③ Going concern assumption, that is, it is assumed that the assessed unit will continue to operate in the foreseeable future based on its existing assets and resource conditions.

We will not stop operating for various reasons in the future, but will continue to operate legally.

2. Particularity assumption: ① It is assumed that the accounting policies adopted by the assessed unit after the valuation base date and the accounting policies adopted when preparing this valuation report

The accounting policies used are consistent in important respects;

② It is assumed that the assessed unit will operate based on the existing management methods and management levels after the assessment base date.

The scope and method remain consistent with the current situation;

③ It is assumed that the products or services of the assessed unit will maintain the current market competition after the valuation base date; ④ It is assumed that the R&D capabilities and technological advancement of the assessed unit will remain at the current level after the assessment baseline date.

3. General assumptions:

① It is assumed that the political, economic and social environment of the country and region where the assessed unit is located after the valuation base date will not change.

major changes;

② Assume that there will be no major changes in national macroeconomic policies, industrial policies and regional development policies after the assessment base date. change;

③Assume interest rates, exchange rates, tax bases and tax rates, and policy collection fees related to the assessed unit

There will be no significant changes after the valuation base date;

④ It is assumed that the management of the assessed unit after the valuation base date is responsible, stable, and capable of taking on the responsibilities their duties;

⑤ Assume that the assessed unit fully complies with all relevant laws and regulations;

⑥ It is assumed that there is no force majeure that will have a significant adverse impact on the assessed unit after the valuation base date.

4. The evaluation conclusion in this evaluation report is based on the above assumptions. When the above assumptions

When major changes occur, this appraisal agency and the signing asset appraiser will not be responsible for any inferences due to changes in assumptions. Responsibility for deriving different assessment conclusions.

(4) Evaluation conclusion

Book value of total assets of Shanghai Ruihongdi Pharmaceutical Co., Ltd. on the valuation base date, December 31, 2025

is 249.7977 million yuan, the book value of total liabilities is 316.0629 million yuan, and the book value of net assets is 316.0629 million yuan.

-66.2652 million yuan. The appraised value of total assets is RMB 1,403,780,800, and the appraised value of total liabilities is RMB 316,062,900.

The appraised value of net assets is 1,087.7179 million yuan, and the appraised value of net assets has increased in value compared with the book value.

1,153.9831 million yuan, with a value-added rate of 1,741.46%.

(2) Pricing rationality analysis

Zhongfa International Asset Appraisal Co., Ltd., the appraisal agency for this transaction, complies with the relevant regulations of the Securities Law. The designated appraisal agency and the handling appraiser have no relationship with the company, the counterparty to the transaction and the target company.

There are actual and anticipated interests other than professional fees; the evaluation agency is independent.

Zhongfa International Asset Appraisal Co., Ltd. adheres to the provisions of laws, administrative regulations and asset appraisal standards.

Adhere to the principles of independence, objectivity and impartiality, adopt the asset-based approach, and follow necessary evaluation procedures to evaluate Shanghai Rui

The market value of Hongdi Pharmaceutical Co., Ltd.’s shareholders’ equity as of December 31, 2025 was assessed. The assessment method chosen is reasonable and consistent with the purpose of the assessment.

This capital increase was determined through negotiation based on the appraised value. The transaction pricing is fair and reasonable and will not harm the company.

actions in the interest of shareholders.

5. Main contents of related-party foreign investment contracts

(1) Parties to the transaction Target company: Ruihongdi

Capital increase parties: the company, Hengrui Group, Shengdi Fund, Yingtai Asset Management

(2) Capital increase and delivery

All parties agree that in this capital increase, the capital increase parties will increase capital to the target company by a total of RMB 750 million. The target company's new registered capital increased by RMB 98.6842 million, making the target company's registered capital increase from RMB

RMB 131,578,900 increased to RMB 230,263,200. Among them, Hengrui Medicine increased its investment with its own funds.

RMB 285 million, and the target company’s new registered capital was RMB 37.5 million; Hengrui Group increased its registered capital by RMB 37.5 million;

capital of RMB 210 million, and the subscribed target company’s new registered capital was RMB 27.6316 million; Shengdi

The fund increased its capital by RMB 142.5 million, and the target company's new registered capital was RMB 18.75 million; Yingtai Asset Management increased its capital by RMB 112.5 million, subscribing to the target company’s new registered capital of RMB

14.8026 million yuan.

The capital increase party shall pay the capital increase to Ruihongdi within two months after the signing of the agreement. From any capital increase method

From the date of payment of the corresponding capital increase price under this Agreement, the Company shall

shall enjoy corresponding rights and assume corresponding obligations according to the relevant provisions of the Company's Articles of Association and this Agreement. Within ten working days after receiving the capital increase price, Ruihongdi submitted to the Market Supervision and Administration Bureau the conditions for this capital increase.

A formal industrial and commercial change registration application shall be provided to each capital increase party within three working days after completing the change registration.

Please obtain an electronic scanned copy of the updated business license.

(3) Liability for breach of contract

The failure of either party to perform its obligations under this Agreement shall constitute a breach of this Agreement. breach of contract Each party shall compensate the non-defaulting party for all losses caused to the non-defaulting party due to its breach of contract, including the losses incurred by the non-defaulting party due to the breach of contract.

Related Fees.

(4) Effective

This Agreement shall come into effect on the date it is signed and sealed by all parties to the Agreement.

6. The impact of related-party external investment on listed companies This capital increase will further optimize Ruihongdi’s asset structure and promote its business development, in line with the company’s strategic development.

exhibition needs. This capital increase will not have a significant impact on the company’s financial status and operating results, and there is no possibility of new

Increased related transactions, horizontal competition, external guarantees or occupation of non-operating funds will not damage the company and the overall

interests of individual shareholders, especially small and medium shareholders.

7. Risk warning for overseas investment The target company is engaged in drug research and development, and the drug development, clinical trial approval, and production cycle are long and complex.

Drug research and development and launch are easily affected by some uncertain factors. Investors are advised to be cautious.

Make decisions and pay attention to guarding against investment risks.

8. Review procedures that should be performed for the related-party transaction (1) Opinions of special meeting of independent directors

The proposal has been reviewed by a special meeting of independent directors, and the voting result of the special meeting of independent directors was: 4 votes

Agree, 0 votes against, 0 abstentions. A special meeting of independent directors believed that this related transaction would have a negative impact on the company’s financial

It will not have a significant impact on the financial status and operating results, and there will be no harm to the company and all shareholders, especially small and medium-sized enterprises.

shareholder interests. unanimously agreed to this proposal and agreed to submit the above matters to the company's board of directors for review. (2) Review and voting status of the board of directors

The company held the 24th meeting of the ninth board of directors on March 25, 2026, and reviewed and approved

"Proposal on the capital increase and related transactions of the joint-stock company Shanghai Ruihongdi Pharmaceutical Co., Ltd." Voting results

There were 9 votes in favor, 0 votes against, and 0 abstentions. Related directors Sun Piaoyang and Zhang Lianshan abstained from voting.

This related transaction does not need to be submitted to the company's shareholders' meeting for review, and does not need to be approved by relevant departments. 9. Historical related transactions (except daily related transactions) that need special explanation

In addition to the daily related transactions disclosed by the company in its regular reports or interim reports, as of the date of this announcement,

The company has not had any transactions with the same related person or transactions with different related persons in the past 12 months.

Related transactions under the same transaction category.

Announcement is hereby made.

Board of Directors of Jiangsu Hengrui Pharmaceutical Co., Ltd.

March 25, 2026